author-photo

Niels W.C.J. van de Donk

VU University Amsterdam
VU University Medical Center
Utrecht University

227

Papers

6313

Citations

Citation Trend

Filter By

Papers (152) Sort By

Journal Conference Others

Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.

2021 Clinical Chemistry and Laboratory Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (1)
Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.

2021 International Journal of Molecular Sciences
Show All
- Source
- Cite
- Save
Citations (33)
CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (6)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

2021 Elements
Show All
- Source
- Cite
- Save
Citations (0)